Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16672851 | 0.83 | FFAR1 (0.49) | TSHRALDH1A1L3MBTL1SMN1; SMN2FFAR1 | |
| SCHEMBL1904663 | 0.79 | CYP19A1 (0.39) | CYP19A1CYP17A1TSHRL3MBTL1ACACB | |
| SCHEMBL1533096 | 0.79 | ALDH1A1 (0.42) | TSHRALDH1A1GAALMNAHTT | |
| SCHEMBL11540167 | 0.76 | TSHR (0.41) | TSHRALDH1A1LMNAFFAR1 | |
| SCHEMBL22824119 | 0.75 | CYP3A4 (0.40) | CYP19A1CYP17A1TSHRALDH1A1L3MBTL1 | |
| SCHEMBL14762668 | 0.75 | MAPT (0.48) | TSHRALDH1A1L3MBTL1GAAHTT | |
| SCHEMBL11307778 | 0.75 | FFAR1 (0.49) | TSHRALDH1A1LMNAFFAR1 | |
| SCHEMBL28524514 | 0.73 | FFAR1 (0.60) | TSHRALDH1A1ACACBFFAR1 | |
| SCHEMBL14762470 | 0.72 | ALDH1A1 (0.41) | TSHRALDH1A1SMN1; SMN2FFAR1 | |
| SCHEMBL10516365 | 0.72 | CYP19A1 (0.54) | CYP19A1CYP17A1TSHRALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| EP-1979320-B1 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| EP-1979320-B1 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2007087135-A2 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | GRM5, GRM1, GRIN1 | CYP19A1 3167/4885CYP17A1 4215/4885TSHR 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.